We are an early stage biotech company that has created a monoclonal antibody(s) for the treatment of Sickle Cell Disease. We are targeting a receptor that has ubiquitous possibilities. Our goal is to provide the global village access to compounds that improve patients' quality of life and outcomes through our novel scientific technology. D-10 strives to make our monoclonal antibody(s) available at an affordable price for the patient population that we serve.
